{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:17:15Z","timestamp":1772824635097,"version":"3.50.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008658","name":"Deutsches Krebsforschungszentrum","doi-asserted-by":"publisher","award":["DFG INST 91027\/9-1 FUGG"],"award-info":[{"award-number":["DFG INST 91027\/9-1 FUGG"]}],"id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008658","name":"Deutsches Krebsforschungszentrum","doi-asserted-by":"publisher","award":["DFG INST 91027\/10-1 FUGG"],"award-info":[{"award-number":["DFG INST 91027\/10-1 FUGG"]}],"id":[{"id":"10.13039\/100008658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["394046768 \\u2013 CRC\/SFB 1366"],"award-info":[{"award-number":["394046768 \\u2013 CRC\/SFB 1366"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["259332240 \\u2013 RTG\/GRK 2099"],"award-info":[{"award-number":["259332240 \\u2013 RTG\/GRK 2099"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003542","name":"Ministerium f\u00fcr Wissenschaft, Forschung und Kunst Baden-W\u00fcrttemberg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006693","name":"Arbeitsgemeinschaft Dermatologische Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canlet.2025.217950","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T15:07:51Z","timestamp":1753369671000},"page":"217950","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Neoadjuvant immune checkpoint inhibition improves protection against hepatic melanoma metastasis"],"prefix":"10.1016","volume":"632","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-6149","authenticated-orcid":false,"given":"Sebastian A.","family":"Wohlfeil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Weller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Dietsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis Alexander","family":"Agardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Boschert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila A.","family":"Vormehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Dormann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Straub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"H\u00e4fele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Platten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5718-415X","authenticated-orcid":false,"given":"Sergij","family":"Goerdt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrill","family":"G\u00e9raud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.canlet.2025.217950_bib1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0002-9610(78)90171-X","article-title":"Metastatic pattern of malignant melanoma. A study of 216 autopsy cases","volume":"135","author":"Patel","year":"1978","journal-title":"Am. J. Surg."},{"issue":"16","key":"10.1016\/j.canlet.2025.217950_bib2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.canlet.2025.217950_bib3","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.canlet.2025.217950_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with Anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.canlet.2025.217950_bib5","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/jamaoncol.2018.2668","article-title":"Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600-Mutated metastatic melanoma: pooled analysis of 4 randomized clinical trials","volume":"4","author":"Hauschild","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217950_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217950_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113433","article-title":"Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-line setting","volume":"196","author":"Saberzadeh-Ardestani","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"52","key":"10.1016\/j.canlet.2025.217950_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci. Immunol."},{"issue":"19","key":"10.1016\/j.canlet.2025.217950_bib9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.canlet.2025.217950_bib10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.canlet.2025.217950_bib11","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217950_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9505","article-title":"Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study","volume":"41","author":"Luke","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217950_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","author":"Kirkwood","year":"2023","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.canlet.2025.217950_bib14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217950_bib15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2022.06.041","article-title":"Adjuvant nivolumab versus ipilimumab (checkMate 238 trial): reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria","volume":"173","author":"Larkin","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.canlet.2025.217950_bib16","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(22)00559-9","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial","volume":"23","author":"Long","year":"2022","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217950_bib17","doi-asserted-by":"crossref","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: recommendations of the international neoadjuvant melanoma consortium","volume":"20","author":"Amaria","year":"2019","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217950_bib18","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217950_bib19","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1159\/000511925","article-title":"Therapy algorithms for the diagnosis and treatment of patients with early and advanced breast cancer","volume":"15","author":"Schneeweiss","year":"2020","journal-title":"Breast Care"},{"issue":"11","key":"10.1016\/j.canlet.2025.217950_bib20","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.canlet.2025.217950_bib21","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.canlet.2025.217950_bib22","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217950_bib23","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.217950_bib24","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat. Med."},{"issue":"15_suppl","key":"10.1016\/j.canlet.2025.217950_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.10002","article-title":"First safety and efficacy results of PRADO: a phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma","volume":"38","author":"Blank","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.canlet.2025.217950_bib26","doi-asserted-by":"crossref","first-page":"9502","DOI":"10.1200\/JCO.2021.39.15_suppl.9502","article-title":"Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (Rela) for patients (pts) with resectable clinical stage III melanoma","volume":"39","author":"Amaria","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217950_bib27","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.canlet.2025.217950_bib28","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat. Med."},{"issue":"7934","key":"10.1016\/j.canlet.2025.217950_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.canlet.2025.217950_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217950_bib31","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.217950_bib32","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/0008-5472.CAN-18-1752","article-title":"Hepatic endothelial notch activation protects against liver metastasis by regulating endothelial-tumor cell adhesion independent of angiocrine signaling","volume":"79","author":"Wohlfeil","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217950_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12967-022-03255-4","article-title":"Angiogenic and molecular diversity determine hepatic melanoma metastasis and response to anti-angiogenic treatment","volume":"20","author":"Wohlfeil","year":"2022","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.217950_bib34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2567.1997.00412.x","article-title":"Comparison of intrahepatic lymphocytes from normal and growth hormone transgenic mice with chronic hepatitis and liver cancer","volume":"90","author":"Hardy","year":"1997","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.canlet.2025.217950_bib35","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1038\/s41467-021-23324-4","article-title":"Interpretation of T cell states from single-cell transcriptomics data using reference atlases","volume":"12","author":"Andreatta","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.canlet.2025.217950_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","article-title":"Dictionary learning for integrative, multimodal and scalable single-cell analysis","volume":"42","author":"Hao","year":"2024","journal-title":"Nat. Biotechnol."},{"issue":"12","key":"10.1016\/j.canlet.2025.217950_bib37","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat. Methods"},{"key":"10.1016\/j.canlet.2025.217950_bib38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12688\/f1000research.22139.1","article-title":"scRepertoire: an R-based toolkit for single-cell immune receptor analysis","volume":"9","author":"Borcherding","year":"2020","journal-title":"F1000Res."},{"issue":"5","key":"10.1016\/j.canlet.2025.217950_bib39","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221952","article-title":"IFN-\u03b3 signature enables selection of neoadjuvant treatment in patients with stage III melanoma","volume":"220","author":"Reijers","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2025.217950_bib40","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.csbj.2021.06.043","article-title":"UCell: robust and scalable single-cell gene signature scoring","volume":"19","author":"Andreatta","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.canlet.2025.217950_bib41","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1038\/s41467-020-15543-y","article-title":"Single-cell transcriptomics identifies an effectorness gradient shaping the response of CD4","volume":"11","author":"Cano-Gamez","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2025.217950_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.immuni.2019.05.014","article-title":"Single-cell RNA sequencing of the T helper cell response to house dust mites defines a distinct gene expression signature in airway Th2 cells","volume":"51","author":"Tibbitt","year":"2019","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.canlet.2025.217950_bib43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"issue":"24","key":"10.1016\/j.canlet.2025.217950_bib44","doi-asserted-by":"crossref","first-page":"5971","DOI":"10.1158\/1078-0432.CCR-16-0460","article-title":"Role of the microenvironment in liver metastasis: from Pre- to prometastatic niches","volume":"22","author":"Brodt","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217950_bib45","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"issue":"16_suppl","key":"10.1016\/j.canlet.2025.217950_bib46","doi-asserted-by":"crossref","first-page":"9539","DOI":"10.1200\/JCO.2022.40.16_suppl.9539","article-title":"The interferon-gamma (IFN-y) signature from baseline tumor material predicts pathologic response after neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma","volume":"40","author":"Reijers","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217950_bib47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41591-019-0734-6","article-title":"Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma","volume":"26","author":"Fairfax","year":"2020","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.canlet.2025.217950_bib48","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.4049\/jimmunol.150.10.4303","article-title":"Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis","volume":"150","author":"Ratner","year":"1993","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217950_bib49","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2007-11-120998","article-title":"Tumor-specific Th17-polarized cells eradicate large established melanoma","volume":"112","author":"Muranski","year":"2008","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.canlet.2025.217950_bib50","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/0008-5472.CAN-14-2524","article-title":"Blocking tumor necrosis factor \u03b1 enhances CD8 T-cell-Dependent immunity in experimental melanoma","volume":"75","author":"Bertrand","year":"2015","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2025.217950_bib51","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1084\/jem.20090207","article-title":"IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway","volume":"206","author":"Wang","year":"2009","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.canlet.2025.217950_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ni1424","article-title":"Transcription factors T-bet and Runx3 cooperate to activate ifng and silence Il4 in T helper type 1 cells","volume":"8","author":"Djuretic","year":"2007","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217950_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1084\/jem.194.2.165","article-title":"Interferon gamma stabilizes the T helper cell type 1 phenotype","volume":"194","author":"Zhang","year":"2001","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.canlet.2025.217950_bib54","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1261242","article-title":"IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients","volume":"6","author":"Tallerico","year":"2017","journal-title":"OncoImmunology"},{"issue":"7854","key":"10.1016\/j.canlet.2025.217950_bib55","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"issue":"7967","key":"10.1016\/j.canlet.2025.217950_bib56","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4 + T cell-induced inflammatory cell death controls immune-evasive tumours","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2025.217950_bib57","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1186\/s12967-022-03807-8","article-title":"Pharmaceutical targeting Th2-mediated immunity enhances immunotherapy response in breast cancer","volume":"20","author":"Chen","year":"2022","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.canlet.2025.217950_bib58","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217950_bib59","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"43","key":"10.1016\/j.canlet.2025.217950_bib60","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102849118","article-title":"Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response","volume":"118","author":"Gangaev","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"45","key":"10.1016\/j.canlet.2025.217950_bib61","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.canlet.2025.217950_bib62","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1093\/bioinformatics\/btac582","article-title":"Propeller: testing for differences in cell type proportions in single cell data","volume":"38","author":"Phipson","year":"2022","journal-title":"Bioinformatics"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:35:26Z","timestamp":1772804126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525005191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":62,"alternative-id":["S0304383525005191"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217950","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant immune checkpoint inhibition improves protection against hepatic melanoma metastasis","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217950","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217950"}}